Bencich John
Bencich John's purchase track record
Bencich John has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2024 | ACHV | $46K | +17.9% | -2.0% | +7.8% |
| 5/30/2023 | ACHV | $28K | -24.0% | -6.1% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Lisata Therapeutics adds Jeffrey Farrow to board. Lisata Therapeutics, the parent company of Achieve Life Sciences, has appointed Jeffrey Farrow to its board of directors. Farrow is a veteran in biopharma finance, bringing experience in capital markets and corporate strategy. This move signals a focus on strengthening the company's financial leadership and governance structure as it navigates its current market position.
Transaction History
| AEON | ▲ Buy | Grant | 754,717 | $0 | 4/2/2026 | View on chart |
| ACHV | ▲ Buy | Grant | 5,000 | $18K | 8/16/2024 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 25,000 | $0 | 4/19/2024 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 6,088 | $27K | 4/19/2024 | View on chart |
| ACHV | ▲ Buy | Open Market | 10,000 | $46K | 3/4/2024 | View on chart |
| ACHV | ▲ Buy | Open Market | 5,000 | $28K | 5/30/2023 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 7,500 | $0 | 4/28/2023 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 1,827 | $15K | 4/28/2023 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 7,324 | $50K | 4/21/2023 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 25,000 | $0 | 4/21/2023 | View on chart |
| ACHV | ▲ Buy | Open Market | 22,000 | — | 11/18/2022 | View on chart |
| ACHV | ▲ Buy | Grant | 3,059 | $13K | 8/16/2022 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 7,500 | $0 | 4/28/2022 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 1,827 | $14K | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.